Search | Clinical Trials Finder

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Santa Barbara, California • Naples, Florida + 5 more

Conditions: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions: Smartphone Text Messaging, Fitbit Charge HR; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: NX1011; Drug
Lead sponsor: NITROX, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kissimmee, Florida

Conditions: Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
Interventions: PET-CT Imaging with [89Zr]-bevacizumab; Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions: L606, Placebo; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Scottsdale, Arizona • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions: iNO; Combination Product
Lead sponsor: Bellerophon; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions: Placebo, LAM-001; Drug
Lead sponsor: OrphAI Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 11 more

Conditions: Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Interventions: tadalafil and ambrisentan upfront combination therapy; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions: Opsumit 10 Mg Tablet; Drug
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions: higher oxygen saturation target using Nellcor pulse oximetry sensors, lower oxygen saturation target using Nellcor pulse oximetry sensors; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Month to 5 Months
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • New Haven, Connecticut

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Iloprost Inhalation Solution (Ventavis); Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Sarcoidosis, Pulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Charleston, South Carolina

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Rochester, Minnesota + 4 more

Conditions: PAH
Interventions: CXA-10; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
Interventions: L-Glutamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 4 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Oakland, California

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Frespaciguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 18
States / cities: San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more

Search by objective public record fields.

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

A Mobile Health Intervention in Pulmonary Arterial Hypertension

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Angiogenic Imaging in Pulmonary Arterial Hypertension

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

Heart Disease in Sickle Cell Anemia

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Long-Term Open-Label Extension Study of Oral Levosimendan

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD